Individuals with genetic gain-of-function variation in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene are at an increased risk of cardiovascular disease, including ischemic stroke. While PCSK9 inhibitors (PCSK9i) are effective in reducing cardiovascular disease risk and ischemic stroke risk, novel genomic technologies including the use of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 complex-mediated delivery and adenine base editing (ABE) enable promising new therapeutic and preventative approaches. In this paper we discuss ongoing work into PCSK9 base editing and highlight future directions relevant to cardiovascular disease and ischemic stroke.
Keywords: Proprotein convertase subtilisin-kexin type 9 (PCSK9); adenine base editors; cardiovascular disease (CVD); cholesterol; clustered regularly interspaced short palindromic repeats (CRISPR); gene editing; genetics; ischemic stroke; low-density lipoprotein-cholesterol (LDL-C).